Annovis Bio
ANVS
56 hedge funds and large institutions have $10.5M invested in Annovis Bio in 2026 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 13 increasing their positions, 10 reducing their positions, and 9 closing their positions.
136% more call options, than puts
Call options by funds: $1.03M | Put options by funds: $438K
56% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 9
30% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 10
6% more funds holding
Funds holding: 53 → 56 (+3)
0.66% more ownership
Funds ownership: 15.99% → 16.65% (+0.66%)
28% less capital invested
Capital invested by funds: $14.7M → $10.5M (-$4.14M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$1.27M |
| 2 |
Renaissance Technologies
New York
|
+$953K |
| 3 |
Two Sigma Investments
New York
|
+$208K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$125K |
| 5 |
SG
Sherry Group
Mountain Home,
Arkansas
|
+$82.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$689K |
| 2 |
DADC
D.A. Davidson & Co
Great Falls,
Montana
|
-$556K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$233K |
| 4 |
OAC
OMERS Administration Corp
Toronto,
Ontario, Canada
|
-$215K |
| 5 |
VF
Virtu Financial
New York
|
-$91K |
ANVS Hedge Fund Activity: Q1 2026 in Review
56 of the 8,192 institutional investors tracked by Wall St. Rank reported a position in Annovis Bio (ANVS) for Q1 2026, worth a combined $10.5M — down 28% from $14.7M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new ANVS positions and 9 closed out — a net gain of 5 holders — while 13 added to existing stakes and 10 trimmed.
The largest buyer was Marshall Wace, adding an estimated $1.27M. The largest seller was Jane Street, exiting entirely with an estimated $689K sold.
- 56 institutional investors held Annovis Bio (ANVS) as of Q1 2026, up from 53 in Q4 2025.
- Funds reported $10.5M of Annovis Bio stock for Q1 2026, down 28% quarter-over-quarter.
- 14 funds opened new Annovis Bio positions in Q1 2026 and 9 closed out, a net change of +5 holders.
- The largest Annovis Bio buyer in Q1 2026 was Marshall Wace, an estimated $1.27M added.
- The largest Annovis Bio seller in Q1 2026 was Jane Street, an estimated $689K sold.
Based on aggregated 13F filings for Q1 2026.